Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous cluster immunotherapy with CLUSTOID Birke in birch pollen allergy
2022-001587-97Phase 2Completed
- Sponsor
- ROXALL Medizin GmbH
- Start
- Dec 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic rhinitis (AR) and allergic conjunctivitis (AC) comparing CLUSTOID Birke immunotherapy with Placebo (2 arms). Primary endpoint: Combined Symptom and Medication Score (CSMS). Started Dec 2022; status: completed.
02
Drugs
birch pollen allergoid
03
Conditions
allergic rhinitis (AR)allergic conjunctivitis (AC)
Beyond the preview
Go deeper on 2022-001587-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001587-97.